SCHEMBL17243647

SCHEMBL17243647

Cn1ccc2cnc3ccsc3c21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.39
ADORA1 P30542 6/20 0.39
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
AXL P30530 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
MKNK2 Q9HBH9 1/20 0.36
PDPK1 O15530 1/20 0.34
PARP1 P09874 1/20 0.34
PIK3CB P42338 1/20 0.33
ACVR1 Q04771 1/20 0.33
MAPT P10636 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
HTR3A P46098 1/20 0.33
PIK3CD O00329 1/20 0.32
JAK1 P23458 1/20 0.32
TYRO3 Q06418 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
GAA P10253 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17243648 0.80 TLR7 (0.34) ADORA2AADORA1MEN1KMT2AL3MBTL1
SCHEMBL17243646 0.80 PDE7A (0.36) ADORA2AADORA1MEN1KMT2AAXL
SCHEMBL8570253 0.70 AXL (0.45) ADORA2AADORA1MEN1KMT2AAXL
SCHEMBL9412483 0.69 KDM4E (0.50) PDPK1HTR3APIK3CDCYP1A2HTR2C
SCHEMBL30598861 0.69 ALDH1A1 (0.43) MEN1KMT2AAXLMKNK1MKNK2
SCHEMBL28900443 0.69 ALDH1A1 (0.43) MEN1KMT2AAXLMKNK1MKNK2
SCHEMBL21566257 0.67 PIP4K2C (0.38) MEN1KMT2AAXLMKNK1MKNK2
SCHEMBL28471084 0.66 PSMB8 (0.39) MEN1KMT2AAXLMKNK1MKNK2
SCHEMBL30598793 0.66 PSMB8 (0.39) MEN1KMT2AAXLMKNK1MKNK2
SCHEMBL25258664 0.65 TLR7 (0.47)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180148460-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2018-05-31 US disclosed
US-9908895-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE CORPORATION (US) 2018-03-06 US disclosed
US-9777017-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2017-10-03 US disclosed
US-20160024109-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE HOLDINGS CORPORATION 2016-01-28 US disclosed
US-20160015695-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS INCYTE CORPORATION 2016-01-21 US disclosed
US-9181271-B2 Tricyclic fused thiophene derivatives as JAK inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160015695-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 ADORA2A 4025/4885ADORA1 4689/4885MEN1 3821/4885
US-20180148460-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 ADORA2A 4025/4885ADORA1 4689/4885MEN1 3821/4885
US-20160024109-A1 TRICYCLIC FUSED THIOPHENE DERIVATIVES AS JAK INHIBITORS JAK1, JAK3, JAK2 ADORA2A 4025/4885ADORA1 4689/4885MEN1 3821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.